Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
SymbolLON:SUMM
CUSIPN/A
Phone+44-1235-443939
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-102.61%
Return on Equity-72.51%
Return on Assets-15.82%
Miscellaneous
EmployeesN/A
Outstanding Shares70,630,000
Market Cap£137.73 million
Summit Therapeutics (LON:SUMM) Frequently Asked Questions
What is Summit Therapeutics' stock symbol?
Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."
How were Summit Therapeutics' earnings last quarter?
Summit Therapeutics PLC (LON:SUMM) released its quarterly earnings data on Tuesday, June, 5th. The company reported ($8.00) earnings per share for the quarter, beating the consensus estimate of ($10.60) by $2.60. Summit Therapeutics had a negative return on equity of 72.51% and a negative net margin of 102.61%. View Summit Therapeutics' Earnings History.
Who are some of Summit Therapeutics' key competitors?
Some companies that are related to Summit Therapeutics include TIGENIX/S (TIG), Rigel Pharmaceuticals (RIGL), OrganiGram (OGI), Stemline Therapeutics (STML), Prothena (PRTA), Civitas Solutions (CIVI), Ra Pharmaceuticals (RARX), Zymeworks (ZYME), Vectura Group (VEC), Arbutus Biopharma (ABUS), Theratechnologies (THERF), Adamas Pharmaceuticals (ADMS), Japara Healthcare (JHC), Antares Pharma (ATRS) and ZEALAND PHARMA/S (ZEAL).
Who are Summit Therapeutics' key executives?
Summit Therapeutics' management team includes the folowing people:
- Mr. Glyn O. Edwards, CEO & Exec. Director (Age 62)
- Mr. Erik Ostrowski, Chief Financial Officer (Age 45)
- Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 52)
- Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 68)
- Ms. Michelle Avery, Director of Investor Relations
How do I buy shares of Summit Therapeutics?
Shares of SUMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Summit Therapeutics' stock price today?
One share of SUMM stock can currently be purchased for approximately GBX 34.50.
How big of a company is Summit Therapeutics?
Summit Therapeutics has a market capitalization of £137.73 million.
What is Summit Therapeutics' official website?
How can I contact Summit Therapeutics?
Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The company can be reached via phone at +44-1235-443939.
MarketBeat Community Rating for Summit Therapeutics (LON SUMM)
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote "Outperform" if you believe SUMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
